Relay Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
March 25, 2021 16:05 ET
|
Relay Therapeutics, Inc.
Advanced two programs, RLY-1971 and RLY-4008, into clinical development, and on track to initiate IND enabling studies with PI3Kα mutant selective inhibitor in 2021 Entered into a global...
Relay Therapeutics to Present Preclinical Data on RLY-4008 at AACR Annual Meeting
March 10, 2021 16:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...
Relay Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2021 Oncology Day
February 04, 2021 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on...
Relay Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
January 06, 2021 06:00 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021...
Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971
December 14, 2020 06:00 ET
|
Relay Therapeutics, Inc.
Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors Relay Therapeutics will receive $75 million upfront and is eligible to receive an additional $25 million in near-term...
Relay Therapeutics Reports Third Quarter 2020 Financial Results
November 12, 2020 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor
September 03, 2020 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...
Relay Therapeutics Reports Second Quarter 2020 Financial Results
August 27, 2020 06:50 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...
Relay Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 20, 2020 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...
Relay Therapeutics Announces Pricing of Initial Public Offering
July 15, 2020 20:50 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...